↓ Skip to main content

Dove Medical Press

Article Metrics

Clinical development of nintedanib for advanced non-small-cell lung cancer

Overview of attention for article published in Therapeutics and Clinical Risk Management, November 2015
Altmetric Badge

About this Attention Score

  • Above-average Attention Score compared to outputs of the same age (57th percentile)
  • Above-average Attention Score compared to outputs of the same age and source (64th percentile)

Mentioned by

twitter
6 tweeters
reddit
1 Redditor

Citations

dimensions_citation
10 Dimensions

Readers on

mendeley
27 Mendeley
Title
Clinical development of nintedanib for advanced non-small-cell lung cancer
Published in
Therapeutics and Clinical Risk Management, November 2015
DOI 10.2147/tcrm.s76646
Pubmed ID
Authors

Isamu Okamoto, Masayuki Takeda, Kazuhiko Nakagawa

Abstract

Angiogenesis is an essential process in the development, growth, and metastasis of malignant tumors including lung cancer. Several angiogenesis inhibitors have been developed as potential therapies for non-small-cell lung cancer (NSCLC). Nintedanib is a small-molecule tyrosine kinase inhibitor that targets receptors for vascular endothelial growth factor, platelet-derived growth factor, and fibroblast growth factor as well as RET (rearranged during transfection) and Flt3. When administered as monotherapy, nintedanib was well tolerated at doses up to 250 mg or 200 mg twice daily in European and Japanese patients, respectively, with liver toxicity featuring prominently among dose-limiting toxicities in both populations. A recent Phase III trial demonstrated that treatment with the combination of nintedanib and docetaxel resulted in a significant and clinically meaningful improvement in both progression-free survival and overall survival compared with docetaxel alone in predefined NSCLC patients with adenocarcinoma tumor histology. Although the incidence of elevated alanine aminotransferase or aspartate aminotransferase as well as of diarrhea was higher in patients treated with nintedanib plus docetaxel, most of these adverse events were manageable with supportive treatment or dose reduction. The results of completed and ongoing clinical trials of nintedanib monotherapy and combination therapy for the treatment of NSCLC are summarized in this study.

Twitter Demographics

The data shown below were collected from the profiles of 6 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 27 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 27 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 4 15%
Other 3 11%
Researcher 3 11%
Student > Master 3 11%
Student > Postgraduate 2 7%
Other 5 19%
Unknown 7 26%
Readers by discipline Count As %
Medicine and Dentistry 7 26%
Pharmacology, Toxicology and Pharmaceutical Science 4 15%
Agricultural and Biological Sciences 2 7%
Mathematics 1 4%
Nursing and Health Professions 1 4%
Other 4 15%
Unknown 8 30%

Attention Score in Context

This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 06 December 2015.
All research outputs
#7,468,944
of 22,833,393 outputs
Outputs from Therapeutics and Clinical Risk Management
#409
of 1,264 outputs
Outputs of similar age
#96,222
of 284,455 outputs
Outputs of similar age from Therapeutics and Clinical Risk Management
#19
of 54 outputs
Altmetric has tracked 22,833,393 research outputs across all sources so far. This one is in the 44th percentile – i.e., 44% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,264 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.5. This one has gotten more attention than average, scoring higher than 58% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 284,455 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 57% of its contemporaries.
We're also able to compare this research output to 54 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 64% of its contemporaries.